Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Neurol ; 14: 171, 2014 Sep 10.
Article in English | MEDLINE | ID: mdl-25204350

ABSTRACT

BACKGROUND: BICAMS (Brief International Cognitive Assessment for Multiple Sclerosis) has been recently developed as brief, practical and universal assessment tool for cognitive impairment in MS subjects. It includes the Symbol Digit Modalities Test (SDMT), the California Verbal Learning Test-2 (CVLT2) and the Brief Visuospatial Memory Test-Revised (BVMT-R) . In this study we aimed at gathering regression based normative data for the BICAMS battery in the Italian population. METHODS: Healthy subjects were consecutively recruited among patient friends and relatives. Corrections for demographics were calculated using multivariable linear regression models. Test-retest reliability was assessed using the Pearson correlation coefficient. RESULTS: The BICAMS battery was administered to 273 healthy subjects (180 women, mean age 38.9 ± 13.0 years, mean education 14.9 ± 3.0 years). Test-retest reliability was good for all the tests. CONCLUSIONS: The study provided normative data of the BICAMS for the Italian population confirming good test-retest reliability which can facilitate the use of the battery in clinical practice, also for longitudinal patient assessments.


Subject(s)
Cognition Disorders/diagnosis , Multiple Sclerosis/diagnosis , Neuropsychological Tests/standards , Adolescent , Adult , Aged , Cognition Disorders/etiology , Female , Healthy Volunteers , Humans , Italy , Male , Middle Aged , Multiple Sclerosis/complications , Reference Values , Reproducibility of Results , Young Adult
2.
Oncologist ; 14(11): 1051-60, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19897535

ABSTRACT

PURPOSE: Pathological complete response (pCR) to primary chemotherapy is the main determinant for improved disease-free survival (DFS) and overall survival (OS). The primary endpoints of our study were the long-term DFS and OS rates in homogeneously treated stage IIIB breast cancer patients who failed to achieve a pCR (

Subject(s)
Breast Neoplasms/pathology , Breast Neoplasms/therapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/metabolism , Combined Modality Therapy , Disease-Free Survival , Female , Follow-Up Studies , Humans , Lymph Nodes , Lymphatic Metastasis , Mastectomy , Middle Aged , Neoplasm Staging , Prognosis , Radiotherapy Dosage , Receptor, ErbB-2/metabolism , Survival Rate , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...